truthupfront-business-logo

Daiichi Sankyo Ranbaxy Arbitration Award: The Real Losses

Daiichi Sankyo Ranbaxy Arbitration Award

Table Of Contents

Ten years after winning the Rs 3,500 crore Daiichi Sankyo Ranbaxy arbitration award against former promoters Malvinder and Shivinder Singh, the Japanese pharmaceutical giant has lost 32% of its true repatriable value. This erosion stems from a 30% Indian Rupee depreciation against the US Dollar since 2016, plus an estimated Rs 100 crore in Tier-1 Indian legal fees.

How much has Daiichi lost on the Rs 3,500 crore award?

Even if the original principal of Rs 2,562 crore plus accrued interest is paid in full tomorrow, the net conversion value has dropped by $172 million.

The Rs 3,500 crore figure repeated in court documents is an incomplete metric. Indian courts mandate an interest rate of 4.44% on the principal to account for the time value of money. That calculation assumes the capital remains domestic.

Daiichi requires the funds globally. A financial model calculating the present value of the award converted to US Dollars in April 2016 versus September 2026 outlines the deficit.

How did INR depreciation affect the Daiichi award?

The Indian Rupee’s 30% depreciation against the US Dollar over the last decade cut the principal’s global purchasing power to $364 million.

On April 29, 2016, the Singapore International Arbitration Centre (SIAC), a neutral dispute resolution body used for cross-border corporate contracts, issued the award. On that date, Rs 3,500 crore converted to roughly $525 million at the prevailing exchange rate of Rs 66.44 to the dollar.

Today, that rate sits at nearly Rs 96 to the dollar, according to historical exchange rate data from the Reserve Bank of India.

When applied to the base award, this macro currency shift alone zeroes out the 4.44% statutory interest gains.

What are the legal fees for Daiichi’s 10-year enforcement?

Maintaining elite legal representation over ten years of court hearings has cost Daiichi an estimated Rs 100 crore ($10.4 million).

Daiichi opted to hire Tier-1 Senior Advocates, designated litigation specialists in the Indian Supreme Court and High Courts who command millions of rupees per appearance, to enforce the award.

The August 31, 2026, Delhi High Court judgment alone lists over 15 separate execution applications filed by Daiichi. The company appeared supported by multiple senior advocates and briefing law firms over dozens of hearings.

Based on standard market-rate fee estimates for Senior Advocates over the documented decade of appearances, this operational cost further reduces the depreciated currency value. Subtracting this legal spend yields the final, adjusted net present value: roughly $354 million.

Why is the Daiichi Sankyo Ranbaxy arbitration award still stalled?

The enforcement remains deadlocked because civil courts cannot hand Daiichi assets that a criminal court has frozen as proceeds of crime.

Following criminal charges against the Singh brothers, the Enforcement Directorate (ED), India’s federal economic intelligence agency, attached their assets under the Prevention of Money Laundering Act.

The Indian judicial system processes civil executions through statutory appeals designed to prevent erroneous seizures. The recent September 2026 Supreme Court of India’s refusal to halt a forensic audit into the Singh brothers’ transactions guarantees further hearings and continued billing.

How does the Daiichi case impact foreign investment risk in India?

Foreign capital allocators now build this specific 10-year depreciation curve into their initial Indian deal valuations.

Cross-border M&A lawyers and litigation funders use this timeline as a baseline to model risk premiums. Companies entering the market price in the possibility that contract enforcement will require a decade of legal fees and currency exposure.

“Enforcing the ICC award Daiichi Sankyo obtained against Ranbaxy’s promoters took years of Indian court proceedings,” notes a recent legal analysis on contractual pathologies published by The Legal 500.

Frequently Asked Questions

How much was the original Daiichi-Ranbaxy arbitration award? The original 2016 arbitration award issued by the SIAC was for a base principal of Rs 2,562 crore, plus 4.44% interest. This pushed the nominal total the Singh brothers owed Daiichi Sankyo to roughly Rs 3,500 crore.

Why hasn’t Daiichi received the money yet? The funds are stalled primarily due to a jurisdictional conflict. Daiichi holds a civil claim to the Singh brothers’ assets, but the Enforcement Directorate has criminally attached those same assets under the Prevention of Money Laundering Act, preventing their liquidation.

How much has the Daiichi award lost to currency depreciation? The award has lost approximately 30% of its global purchasing power against the US Dollar since 2016. Converting the Rs 3,500 crore in 2016 equaled $525 million, while converting the identical rupee amount at 2026 exchange rates yields $364 million.

Author - Truthupfront
Updated On - September 29, 2026
Published On - September 29, 2026
[wpdiscuz_comments]